Albireo Pharma Inc (NASDAQ:ALBO) has coverage initiated with a Buy ➝ Buy rating and $62.00 price target

Analyst Ratings For Albireo Pharma Inc (NASDAQ:ALBO)

Story continues below

Today, HC Wainwright initiated coverage on Albireo Pharma Inc (NASDAQ:ALBO) with a Buy with a price target of $62.00.

There are 5 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.

The current consensus rating on Albireo Pharma Inc (NASDAQ:ALBO) is Buy with a consensus target price of $57.75 per share, a potential 102.28% upside.

Some recent analyst ratings include

  • 2/28/2019-Albireo Pharma Inc (NASDAQ:ALBO) has coverage initiated with a Buy ➝ Buy rating and $62.00 price target
  • 1/25/2019-Albireo Pharma Inc (NASDAQ:ALBO) had its Buy rating reiterated by Wedbush with a $69.00 price target
  • 11/14/2018-Albireo Pharma Inc (NASDAQ:ALBO) had its Buy rating reiterated by Cowen
  • 11/13/2018-Albireo Pharma Inc (NASDAQ:ALBO) had its Buy rating reiterated by Needham & Company LLC with a $50.00 price target
  • 4/20/2018-Albireo Pharma Inc (NASDAQ:ALBO) has coverage initiated with a Buy rating and $50.00 price target
  • 11/15/2017-Albireo Pharma Inc (NASDAQ:ALBO) has coverage initiated with a Buy ➝ Buy rating and $92.00 price target
  • On 11/13/2018 Ronald Harold Wilfred Cooper, Insider, bought 1,026 with an average share price of $25.02 per share and the total transaction amounting to $25,670.52.
  • On 8/14/2018 Ronald Harold Wilfred Cooper, Insider, bought 788 with an average share price of $31.85 per share and the total transaction amounting to $25,097.80.
  • On 6/13/2018 Jan Mattsson, COO, sold 25,000 with an average share price of $32.26 per share and the total transaction amounting to $806,500.00.
  • On 1/30/2018 Phase4 Partners Ltd, Major Shareholder, sold 100,000 with an average share price of $34.44 per share and the total transaction amounting to $3,444,000.00.
  • On 1/25/2018 Life Sciences Maste Perceptive, Major Shareholder, bought 275,000 with an average share price of $33.00 per share and the total transaction amounting to $9,075,000.00.
  • On 12/1/2017 Plc Astrazeneca, Major Shareholder, sold 500,000 with an average share price of $21.40 per share and the total transaction amounting to $10,700,000.00.
  • On 12/20/2013 Brian Jg Pereira, Director, sold 4,734 with an average share price of $2.26 per share and the total transaction amounting to $10,698.84.

About Albireo Pharma Inc (NASDAQ:ALBO)
Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate includes A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases. The company also develops Elobixibat, an orally administered IBAT inhibitor for the treatment of chronic constipation and other GI diseases, as well as nonalcoholic steatohepatitis; and A3384 for the treatment of bile acid malabsorption. It has license agreement with EA Pharma for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.

Recent Trading Activity for Albireo Pharma Inc (NASDAQ:ALBO)
Shares of Albireo Pharma Inc closed the previous trading session at 28,55 up +1,75 6,53 % with 30.04 shares trading hands.

An ad to help with our costs